Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Commissioner McClellan Sworn-In; First Focus Is Employee Morale

Executive Summary

FDA Commissioner Mark McClellan, MD/PhD, is beginning his tenure at the agency by emphasizing employee morale and retention

You may also be interested in...



FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER

FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3

FDA Cardio-Renal Head Throckmorton Moves Up To Acting Deputy Of CDER

FDA Cardio-Renal Drug Products Division Director Douglas Throckmorton, MD, is moving up to the position of acting deputy director of CDER, effective May 3

FDA “Strategic Plan” Team Takes Shape: McClellan Names Senior Advisors

FDA Senior Economic Advisor Tomas Philipson, PhD, will work with Commissioner Mark McClellan, MD/PhD, to develop strategic initiatives

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS040799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel